Petros Pharmaceuticals (PTPI) Competitors $0.29 -0.02 (-5.67%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends PTPI vs. JAGX, PHXM, CLRB, INDP, EGRX, CYCN, MYNZ, BCDA, RDHL, and VCNXShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Jaguar Health (JAGX), PHAXIAM Therapeutics (PHXM), Cellectar Biosciences (CLRB), Indaptus Therapeutics (INDP), Eagle Pharmaceuticals (EGRX), Cyclerion Therapeutics (CYCN), Mainz Biomed (MYNZ), BioCardia (BCDA), RedHill Biopharma (RDHL), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Jaguar Health PHAXIAM Therapeutics Cellectar Biosciences Indaptus Therapeutics Eagle Pharmaceuticals Cyclerion Therapeutics Mainz Biomed BioCardia RedHill Biopharma Vaccinex Jaguar Health (NASDAQ:JAGX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations. Do insiders & institutionals hold more shares of JAGX or PTPI? 12.0% of Jaguar Health shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 0.0% of Jaguar Health shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation & earnings, JAGX or PTPI? Petros Pharmaceuticals has lower revenue, but higher earnings than Jaguar Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJaguar Health$10.48M1.04-$41.30MN/AN/APetros Pharmaceuticals$4.02M0.73-$8.16M-$4.76-0.06 Does the media refer more to JAGX or PTPI? In the previous week, Jaguar Health had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Jaguar Health and 0 mentions for Petros Pharmaceuticals. Jaguar Health's average media sentiment score of 0.16 beat Petros Pharmaceuticals' score of 0.00 indicating that Jaguar Health is being referred to more favorably in the media. Company Overall Sentiment Jaguar Health Neutral Petros Pharmaceuticals Neutral Does the MarketBeat Community prefer JAGX or PTPI? Jaguar Health received 1834 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 88.73% of users gave Jaguar Health an outperform vote. CompanyUnderperformOutperformJaguar HealthOutperform Votes183588.73% Underperform Votes23311.27%Petros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Is JAGX or PTPI more profitable? Petros Pharmaceuticals has a net margin of 0.00% compared to Jaguar Health's net margin of -360.13%. Petros Pharmaceuticals' return on equity of -78.22% beat Jaguar Health's return on equity.Company Net Margins Return on Equity Return on Assets Jaguar Health-360.13% -326.62% -67.02% Petros Pharmaceuticals N/A -78.22%-23.50% Which has more risk & volatility, JAGX or PTPI? Jaguar Health has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. SummaryPetros Pharmaceuticals beats Jaguar Health on 8 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.0610.5990.0517.18Price / Sales0.73196.061,116.25117.06Price / CashN/A57.1643.1037.85Price / Book0.075.094.784.78Net Income-$8.16M$151.83M$120.31M$225.60M7 Day Performance-10.73%-2.14%-1.92%-1.23%1 Month Performance9.08%-4.56%13.65%0.46%1 Year Performance-80.88%8.87%28.34%15.24% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.6212 of 5 stars$0.29-5.7%N/A-79.1%$2.95M$4.02M-0.0620News CoverageGap DownJAGXJaguar Health0.2612 of 5 stars$0.91-6.4%N/A-89.9%$10.70M$9.76M0.0050News CoverageGap UpPHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049CLRBCellectar Biosciences1.8004 of 5 stars$0.25-5.7%$17.67+7,102.1%-91.1%$10.12MN/A-0.1510Analyst ForecastGap UpHigh Trading VolumeINDPIndaptus Therapeutics2.8694 of 5 stars$0.98-2.0%$8.50+767.3%-49.6%$9.99MN/A-0.586EGRXEagle Pharmaceuticals1.0034 of 5 stars$0.75+36.4%N/A-89.0%$9.74M$257.55M0.00134Gap DownCYCNCyclerion Therapeutics0.6397 of 5 stars$3.56+3.8%N/A-22.2%$9.65M$194,000.000.0030Gap DownMYNZMainz Biomed2.4922 of 5 stars$4.80-10.4%$120.00+2,400.0%-85.7%$9.61M$917,203.00-0.0730News CoverageGap UpHigh Trading VolumeBCDABioCardia3.3044 of 5 stars$2.09+0.5%$25.00+1,096.2%-79.8%$9.58M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap UpRDHLRedHill Biopharma0.4364 of 5 stars$7.27-2.3%N/A-99.2%$9.31M$3.71M0.00210Gap DownVCNXVaccinex0.9811 of 5 stars$3.54-4.1%N/A-85.7%$9.20M$570,000.00-0.0840Positive News Related Companies and Tools Related Companies Jaguar Health Competitors PHAXIAM Therapeutics Competitors Cellectar Biosciences Competitors Indaptus Therapeutics Competitors Eagle Pharmaceuticals Competitors Cyclerion Therapeutics Competitors Mainz Biomed Competitors BioCardia Competitors RedHill Biopharma Competitors Vaccinex Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTPI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTPI Stock Alerts